Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cell-mediated Immune Responses01:40

Cell-mediated Immune Responses

69.2K
Overview
69.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Multivalent DNA vaccines induce potent cellular responses and prolong BCG-mediated control of Mycobacterium tuberculosis.

Molecular therapy : the journal of the American Society of Gene Therapy·2026
Same author

Optimization of Preclinical Rodent Research Models of Human Shock: Part 2 Trauma, Burn, and the Gut Microbiome.

Shock (Augusta, Ga.)·2026
Same author

T-Cell Clonal Expansion in Peripheral Blood Following Interventional Radiology Procedures for Metastatic Liver Cancer.

Cancers·2026
Same author

Human non-canonical inflammasomes activate CASP3 to limit intracellular Salmonella replication in macrophages.

PLoS pathogens·2026
Same author

Targeted cellular micropharmacies deliver therapeutic agents to the brain.

EMBO molecular medicine·2026
Same author

Trispecific targeting of T cells engineered with TCR mimic antibodies to limit antigen escape.

Journal for immunotherapy of cancer·2026

Related Experiment Video

Updated: Jul 29, 2025

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates
06:10

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

Published on: May 9, 2025

356

Host-cell Interactions of Engineered T cell Micropharmacies.

Christopher M Bourne1,2, Patrick Wallisch2,3, Megan Dacek2,3

  • 1Immunology and Microbial Pathogenesis Program, Weill Cornell Graduate School of Biomedical Sciences, Memorial Sloan Kettering Cancer Center, New York, NY, USA 10065.

Biorxiv : the Preprint Server for Biology
|May 19, 2023
PubMed
Summary

Synthetic Enzyme-Armed KillER (SEAKER) cells, engineered T cells that activate prodrugs, show efficacy against solid tumors in immunocompetent hosts. This adaptable platform overcomes immune barriers, advancing adoptive cell therapy for cancer treatment.

More Related Videos

Ligand Nano-cluster Arrays in a Supported Lipid Bilayer
10:34

Ligand Nano-cluster Arrays in a Supported Lipid Bilayer

Published on: April 23, 2017

7.0K
Use of Single Chain MHC Technology to Investigate Co-agonism in Human CD8+ T Cell Activation
12:09

Use of Single Chain MHC Technology to Investigate Co-agonism in Human CD8+ T Cell Activation

Published on: February 28, 2019

9.8K

Related Experiment Videos

Last Updated: Jul 29, 2025

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates
06:10

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

Published on: May 9, 2025

356
Ligand Nano-cluster Arrays in a Supported Lipid Bilayer
10:34

Ligand Nano-cluster Arrays in a Supported Lipid Bilayer

Published on: April 23, 2017

7.0K
Use of Single Chain MHC Technology to Investigate Co-agonism in Human CD8+ T Cell Activation
12:09

Use of Single Chain MHC Technology to Investigate Co-agonism in Human CD8+ T Cell Activation

Published on: February 28, 2019

9.8K

Area of Science:

  • Immunology
  • Oncology
  • Biotechnology

Background:

  • Adoptive T cell therapy faces challenges in solid tumors due to tumor heterogeneity and immune evasion.
  • Existing engineered T cells require further enhancement for effective solid tumor treatment.
  • Understanding host-T cell interactions is crucial for optimizing engineered T cell therapies.

Conclusions:

  • The SEAKER platform represents a promising advancement in engineered T cell therapy for solid tumors.
  • SEAKER cells effectively overcome host immune responses, offering a new therapeutic strategy.
  • This adaptable technology has broad potential for various adoptive cell therapies.